Beyond LDL: A Comprehensive Approach to Cardiovascular Health
Each year, cardiovascular diseases (CVD) are responsible for more than 4 million deaths in Europe, making them the leading cause of mortality on the continent. These diseases include heart attacks, strokes, and other conditions related to the circulatory system.
For decades, the prevention and treatment of CVD have focused on lowering LDL cholesterol (commonly known as “bad cholesterol”) since it has been identified as a key risk factor in atherosclerosis and artery blockage. However, recent studies have shown that controlling LDL cholesterol alone is not enough, as many patients who manage to lower their levels still develop cardiovascular diseases.
This has led to the need for a broader and more personalized approach to cardiovascular risk prevention, where other biomarkers and metabolic factors play a crucial role.
The Problem of Residual Risk
Residual risk refers to the percentage of patients who, despite achieving target levels of LDL cholesterol, blood pressure, and glucose, continue to suffer cardiovascular events. It is estimated that this risk is around 60-70%, indicating that other factors are still not being fully addressed in the prevention and treatment of CVD.
One of the most revealing studies in this area was published in the American Heart Journal in 2009. This study analyzed over 130,000 patients hospitalized for coronary artery disease and found that more than 50% of them had optimal LDL cholesterol levels at the time of admission. This suggests that LDL cholesterol alone is not a sufficient indicator of cardiovascular risk.
The Role of Lipoproteins in Cardiovascular Health
Cholesterol does not circulate freely in the blood; it requires a special transport system: lipoproteins. These particles, composed of lipids and proteins, are responsible for transporting cholesterol, triglycerides, and other lipids through the bloodstream to the cells that need them.
There are different types of lipoproteins, but the most relevant in cardiovascular health are:
- Low-Density Lipoproteins (LDL): Transport cholesterol from the liver to tissues. An excess of these particles can lead to cholesterol buildup in artery walls, promoting atherosclerosis.
- High-Density Lipoproteins (HDL): Responsible for reverse cholesterol transport, meaning they collect excess cholesterol from tissues and return it to the liver for elimination or reuse. They are traditionally known as “good cholesterol.”
- Very Low-Density Lipoproteins (VLDL): Responsible for transporting triglycerides from the liver to other organs.
Beyond LDL Cholesterol: The Importance of Particle Number and Size
Traditional blood tests measure total cholesterol, LDL, and HDL concentrations. However, these values do not accurately reflect the number and size of lipoproteins carrying that cholesterol, which can be crucial in assessing cardiovascular risk.
LDL Particle Number and Size: It is not just the total amount of LDL cholesterol that matters, but also the number of LDL particles transporting it. Smaller, denser particles can penetrate artery walls more easily, increasing the risk of atherosclerosis.
Atherogenic Dyslipidemia: A common lipid disorder in people with diabetes and obesity, characterized by low HDL cholesterol levels and excess triglycerides. Even if LDL cholesterol appears normal, the number of LDL particles is often high, increasing cardiovascular risk.
The Role of HDL Cholesterol: Traditionally, high HDL cholesterol levels were considered protective against CVD. However, recent studies indicate that it is not just the amount of HDL in the blood that matters but also its quality and functionality. Some HDL particles can lose their ability to remove cholesterol from arteries, becoming dysfunctional.
New Strategies for Cardiovascular Prevention
Since LDL cholesterol alone does not fully explain cardiovascular risk, new strategies have been explored to assess and reduce this risk more precisely.
One of the most promising approaches is the use of metabolomics and advanced lipoprotein characterization.
🔬 What is Metabolomics?
Metabolomics is a discipline that studies the metabolites present in our body. In the case of CVD, it allows us to analyze how different types of lipids and lipoproteins affect cardiovascular risk.
The Role of Liposcale® in Cardiovascular Risk Assessment
One of the most innovative tools in this field is Liposcale®, a test based on Nuclear Magnetic Resonance (NMR) that enables advanced characterization of the lipid profile, providing more detailed and accurate information than traditional cholesterol tests.
With this technology, it is possible to:
✅ Quantify the number and size of LDL, HDL, and VLDL particles, allowing for a more precise cardiovascular risk assessment beyond just measuring total cholesterol.
✅ Analyze the distribution of lipoprotein particles based on their size and concentration, helping to identify dyslipidemia subtypes that may go undetected with a conventional lipid profile.
✅ Evaluate the triglyceride fraction transported in each type of lipoprotein, which is crucial for studying atherogenic dyslipidemias and metabolic syndrome patients.
✅ Detect altered lipid profiles that might be overlooked in standard analyses, such as a high number of small, dense LDL particles, which are highly atherogenic.
✅ Offer a more personalized approach to cardiovascular prevention and treatment, allowing therapeutic strategies to be tailored to each patient based on their actual lipoprotein profile rather than just total cholesterol levels.
The prevention and treatment of cardiovascular diseases have advanced significantly in recent years, but many patients remain at risk despite controlling their LDL cholesterol.
Therefore, adopting a more comprehensive and individualized approach is essential, considering not only LDL cholesterol but also lipoprotein particle number and size, HDL cholesterol function, and other metabolic biomarkers.
Using innovative tools like Liposcale® can improve cardiovascular risk assessment and help develop more effective preventive strategies.
🔎 Would you like to learn more about how metabolomics can help in cardiovascular prevention? Contact us for more information.